Improved Progression-Free Survival in HER2-Negative Metastatic Breast Cancer with Fuzuloparib and Apatinib vs Standard Chemotherapy

Improved Progression-Free Survival in HER2-Negative Metastatic Breast Cancer with Fuzuloparib and Apatinib vs Standard Chemotherapy

Breakthrough in Breast Cancer Treatment: Fuzuloparib and Apatinib Show Promise in Advanced Disease with BRCA Mutations


Metastatic breast cancer affects millions of individuals worldwide and is often challenging to treat. Exciting research has emerged, offering hope for those with HER2-negative disease harboring germline BRCA1/2 mutations.

Impressive Study Results

In a recent phase 3 clinical trial presented during the 2024 ESMO Virtual Plenary session, researchers evaluated the efficacy of fuzuloparib with or without apatinib in patients with metastatic breast cancer and germline BRCA1/2 mutations. The results have sparked enthusiasm among the medical community.

Improved Progression-Free Survival

The study found that both fuzuloparib alone and fuzuloparib combined with apatinib significantly improved progression-free survival (PFS) compared to standard chemotherapy.

  • Fuzuloparib + Apatinib: Median PFS of 11.0 months vs 3.0 months with chemotherapy (HR: 0.27)
  • Fuzuloparib alone: Median PFS of 6.7 months vs 3.0 months with chemotherapy (HR: 0.49)

Secondary Outcomes

Encouraging secondary outcomes were also observed. Fuzuloparib monotherapy significantly improved PFS and objective response rate (ORR) compared to chemotherapy.

  • Median OS: 31.5 months with fuzuloparib vs 21.5 months with chemotherapy (HR: 0.61)
  • ORR: 43.6% with fuzuloparib vs 23.3% with chemotherapy

Safety Profile

The toxicity profile of the treatments was consistent with previous reports. The most common grade 3 or higher adverse events included decreased white blood cell count, anemia, and fatigue.

Expert Perspectives

Dr. Huiping Li, lead researcher of the study, expressed optimism about the findings: “Our results support the use of fuzuloparib plus apatinib or fuzuloparib alone for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.”

Impact on Patient Care

The study’s outcomes have significant implications for patient care. For those with advanced breast cancer and BRCA1/2 mutations, fuzuloparib and apatinib offer new treatment options with the potential to extend progression-free survival.


The ESMO Virtual Plenary study provides compelling evidence for the effectiveness of fuzuloparib and apatinib in treating HER2-negative metastatic breast cancer with germline BRCA1/2 mutations. This research brings renewed hope to patients and paves the way for improved clinical outcomes.

By Divya

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *